Overview

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Status:
Unknown status
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.
Phase:
Phase 1
Details
Lead Sponsor:
Retina Associates of Cleveland, Inc
Collaborator:
Genentech, Inc.
Treatments:
Ranibizumab